Company profile: Antares Pharma
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical products and drug-delivery technologies leveraging proprietary platforms, including ENHANZE® for subcutaneous delivery that can reduce hours-long IV infusions to minutes-long injections; subcutaneous and intramuscular auto-injectors; HYLENEX® recombinant to facilitate dispersion and absorption of injected drugs; XYOSTED® CIII testosterone enanthate injection; and a partner auto-injector pipeline used in five approved therapeutics.
Products and services
- Auto-Injectors: Antares engineers a medical-grade range of auto-injectors for subcutaneous and intramuscular administration, developed to address patient and therapeutic needs and improve compliance
- ENHANZE®: Antares offers a clinical-grade drug delivery technology that facilitates subcutaneous delivery of injected drugs and fluids, potentially reducing treatment time from hours-long IV infusions to minutes-long injections
- XYOSTED® CIII: Antares produces a CIII-designated testosterone enanthate injection used for testosterone replacement therapy in adult males
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Antares Pharma
Neutrolis
HQ: United States
Website
- Description: Provider of candidate-stage, first-in-class anti-NET therapies, including the exDNASETM platform to create molecules that disassemble Neutrophil Extracellular Traps; NTR-L303 to resolve hyperinflammation and disrupt NET-immune complexes; NEU-101 for surface inflammation; and NET biomarkers to identify, treat, and monitor responsive patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neutrolis company profile →
Algernon Pharmaceuticals
HQ: Canada
Website
- Description: Provider of pharmaceutical R&D, in-licensing, and commercialization, advancing NP-120 (Ifenprodil) investigated for chronic cough and idiopathic pulmonary fibrosis, NP-251 (Repirinast) repurposed for chronic kidney disease, and AP-188 (DMT), a naturally occurring psychedelic compound explored for stroke and traumatic brain injury.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algernon Pharmaceuticals company profile →
LEAF Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology and healthcare products, including investigational anticancer drugs targeting solid tumors (LEAF-1401, LEAF-1701) with preclinical results showing reduced metastatic tumor burden in lung cancer models, superior performance in colorectal models, and minimal myelosuppression and gastrointestinal toxicity, plus LEAF-1404, a complex generic anticancer medicine manufactured under global cGMP.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LEAF Pharmaceuticals company profile →
Omeros
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for inflammation and central nervous system disorders, including MASP-2 antibodies (narsoplimab, OMS1029) for lectin pathway diseases such as TA-TMA and lupus nephritis; MASP-3 antibody (OMS906) for PNH; small-molecule PDE7 (OMS527) and PPARγ (OMS405) candidates for addiction; and GPR174 inhibitors for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omeros company profile →
Athersys
HQ: United States
Website
- Description: Provider of an adult-derived, off-the-shelf stem cell therapy platform, MultiStem, for neurological, inflammatory and immune, cardiovascular, and other critical care indications. Conducts clinical trials and programs including MASTERS-2 and TREASURE for stroke, and AMI, PVD, and congestive heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Athersys company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Antares Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Antares Pharma
2.2 - Growth funds investing in similar companies to Antares Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Antares Pharma
4.2 - Public trading comparable groups for Antares Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →